HIMS & HERS HEALTH INC (HIMS) Stock News
NYSE:HIMS - New York Stock Exchange, Inc. - US4330001060 - Common Stock - Currency: USD
HIMS Latest News, Press Relases and Analysis
Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Top movers in Friday's session
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as Wegovy and Ozempic has ended. This could lead to lower sales for companies like Hims & Hers Health, which sell weight-loss medications through their platform.
Why Hims & Hers Health Stock Is Plummeting Today
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized treatments. Also, in another development, FDA resolves semaglutide injection shortage.
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.
Hims & Hers Acquires US-based Peptide Facility
Hims Expands Drug Manufacturing With California Peptide Plant Acquisition
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, including those from weight loss to muscle recovery.
Why the growth investor may take a look at NYSE:HIMS.
A fundamental analysis of (NYSE:HIMS): HIMS & HERS HEALTH INC (NYSE:HIMS) showing high EPS and FCF growth while beating expectations
Hims & Hers Hits New Highs On At-Home Lab Testing Plans: Retail Sees More Room To Run, Analysts Divided
One analyst warned that elevated growth expectations could lead to near-term volatility as the company introduces its FY25 guidance.
Why Is Hims & Hers Health (HIMS) Stock Rocketing Higher Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 24.8% in the afternoon session after the company announced the acquisition of Sigmund (marketed as Trybe Labs), which will allow it to introduce home lab testing through its platform. This capability is expected to help its subscribers test and identify diseases with more accuracy. The data generated from these new features is expected to support AI initiatives like MedMatch, which aim to improve treatment recommendations.
Why Is Hims & Hers Health (HIMS) Stock Rocketing Higher Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 24.8% in the afternoon session after the company announced the acquisition of Sigmund (marketed as Trybe Labs), which will allow it to introduce home lab testing through its platform. This capability is expected to help its subscribers test and identify diseases with more accuracy. The data generated from these new features is expected to support AI initiatives like MedMatch, which aim to improve treatment recommendations.
Hims & Hers Buys Lab to Expand Into At-Home Blood Testing
Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the acquisition of a home blood-testing company.
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.
Hims & Hers: From Viral Ad to Volatile Stock
Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.
Hims & Hers Stock: More Gains Ahead Or A Pullback? Most Retail Traders Bet On This Path
A poll of over 4,000 respondents found that 47% believe the stock will continue its climb past $60, while 44% expect a significant pullback for profit-taking.
Novo Shares Hit as Super Bowl Weight-Loss Ad Shows Copycat Risk
Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat products underscored the challenge to its weight-loss blockbuster drug.